Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Oligonucleotide Therapy Market Size Shifted, And What Is the Outlook Through 2034?

The market size for oligonucleotide therapy has experienced swift expansion in the preceding years. Projected growth from $5.61 billion in 2024 to $6.2 billion in 2025, the market is expected to advance at a compound annual growth rate (CAGR) of 10.5%. The remarkable growth during the historic period can be credited to increased investment in research and development, the introduction of preliminary treatments, growth in gene editing methodologies, early breakthroughs in treatments, and the implementation of RNAi and antisense oligonucleotide.

In the forthcoming years, the market for oligonucleotide therapy is predicted to experience a swift expansion. The market is anticipated to augment to a value of $9.66 billion in 2029, with a compound annual growth rate (CAGR) of 11.8%. This growth in the projected duration is attributed to elements like investments in research and development, increased global market penetration, broadening of therapeutic areas, disease modification stratagems, and regulatory changes. Prevalent trends for the forecast period consist of personalized therapies, advancements in the methods of delivery, progression in RNA interference (RNAI), innovation in antisense oligonucleotide, and the incorporation of gene-editing techniques.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3398&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Oligonucleotide Therapy Market?

The escalation in global cancer cases is predicted to augment the expansion of the oligonucleotide therapy market in the upcoming years. To illustrate, the American Cancer Society projected in January 2022, that the United States would see approximately 1.9 million fresh cancer diagnoses and 609,360 cancer-associated deaths, an average of about 1,670 mortality daily. The top four prevalent cancers globally, including lung, prostate, bowel, and female breast cancer, signify 43 percent of all recent cancer diagnoses. Consequently, the surge in worldwide cancer prevalence is expected to enhance the demand for the oligonucleotide therapy market in the forthcoming era.

Which Key Market Segments Comprise the Oligonucleotide Therapy Market and Drive Its Revenue Growth?

The oligonucleotide therapy market covered in this report is segmented –

1) By Type: Antisense Oligonucleotide, Aptamer, Other Types

2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User

3) By End User: Hospitals, Research Institutes

Subsegments:

1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides, DNA-Targeted Antisense Oligonucleotides, Chemically Modified Antisense Oligonucleotides

2) By Aptamer: DNA Aptamers, RNA Aptamers, Small Molecule Aptamers

3) By Other Types: siRNA (Small Interfering RNA), miRNA (Micro RNA), DNAzyme And Ribozymes, Synthetic Oligonucleotides For Gene Editing

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3398&type=smp

Which Areas Are Leading Regions in the Oligonucleotide Therapy Market Expansion Across the Globe?

North America was the largest region in the oligonucleotide therapy market in 2024. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering theOligonucleotide Therapy Market Direction?

In an effort to minimize the harmful impact on patients, researchers and providers in the oligonucleotide therapy market are investing in scientifically enhancing the therapy design. The newly developed oligonucleotides pave the way for more accurate medical solutions, with the ability to selectively target any gene with minimal side effects. They also aim at targeting specific sequences in patients that cause rare diseases. In the month of April of the year 2023, Qalsody, an antisense oligonucleotide (ASO), received approval from the FDA for treating patients suffering from amyotrophic lateral sclerosis (ALS) related to a mutation in the superoxide dismutase 1 (SOD1) gene. Qalsody aims to diminish the synthesis of SOD1 protein by targeting SOD1 mRNA.

View the full report here:

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

How Is the Oligonucleotide Therapy Market Conceptually Defined?

Oligonucleotide therapy refers to a collective term for cutting-edge molecular-targeting agents that use chemically produced oligonucleotides with single-stranded DNA (DNA) or RNA (RNA) backbones that have the potential for selectivity. Oligonucleotides are made to base-pair with a strand of DNA or RNA for the majority of applications. PCR primers are oligonucleotides’ most popular application (polymerase chain reaction)

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3398

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model